"Fluticasone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.
| Descriptor ID |
D000068298
|
| MeSH Number(s) |
D04.210.500.054.079.129.114
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Fluticasone".
Below are MeSH descriptors whose meaning is more specific than "Fluticasone".
This graph shows the total number of publications written about "Fluticasone" by people in this website by year, and whether "Fluticasone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 0 | 2 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 2 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2016 | 0 | 3 | 3 |
| 2018 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fluticasone" by people in Profiles.
-
Clinic vs?Home Spirometry for Monitoring Lung Function in Patients With Asthma. Chest. 2023 11; 164(5):1087-1096.
-
COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA. Int J Chron Obstruct Pulmon Dis. 2023; 18:407-418.
-
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis. Respir Med. 2022 12; 205:107040.
-
Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate? AAPS J. 2021 03 25; 23(3):48.
-
The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial. Am J Respir Crit Care Med. 2020 11 01; 202(9):1237-1243.
-
Lung function trajectories and chronic obstructive pulmonary disease: current understanding and knowledge gaps. Curr Opin Pulm Med. 2018 03; 24(2):124-129.
-
Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. Am J Respir Crit Care Med. 2018 01 01; 197(1):47-55.
-
Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD. Chest. 2017 Feb; 151(2):340-357.
-
Chinese Herbal Medicine and Salmeterol and Fluticasone Propionate for Chronic Obstructive Pulmonary Disease: Systematic Review and Network Meta-Analysis. Medicine (Baltimore). 2016 May; 95(20):e3702.
-
Assessing biomarkers in a real-world severe asthma study (ARIETTA). Respir Med. 2016 06; 115:7-12.